Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E-H Tan

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialL Paz-Ares, E-H Tan, K O'Byrne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 20, 2011
Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkersE-H Tan, C Goh, W T Lim, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2010
Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 TrialsAnne W M Lee, Stewart Y Tung, Roger K C Ngan, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialL Paz-Ares, E-H Tan, K O'Byrne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 20, 2011
Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkersE-H Tan, C Goh, W T Lim, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2010
Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 TrialsAnne W M Lee, Stewart Y Tung, Roger K C Ngan, et al.
Pageof 8